Boston Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.14M | Sell |
48,532
-5,890
| -11% | -$343K | ﹤0.01% | 529 |
|
|
2025
Q4 | $2.94M | Sell |
54,422
-11,205
| -17% | -$539K | ﹤0.01% | 527 |
|
|
2025
Q3 | $2.96M | Sell |
65,627
-39,832
| -38% | -$1.86M | ﹤0.01% | 514 |
|
|
2025
Q2 | $4.88M | Sell |
105,459
-3,760,655
| -97% | -$185M | 0.01% | 446 |
|
|
2025
Q1 | $236M | Sell |
3,866,114
-24,852
| -0.6% | -$1.45M | 0.28% | 127 |
|
|
2024
Q4 | $220M | Buy |
3,890,966
+529,575
| +16% | +$29.6M | 0.27% | 144 |
|
|
2024
Q3 | $174M | Sell |
3,361,391
-17,438
| -0.5% | -$818K | 0.21% | 168 |
|
|
2024
Q2 | $140M | Sell |
3,378,829
-7,016,591
| -67% | -$314M | 0.17% | 184 |
|
|
2024
Q1 | $561M | Sell |
10,395,420
-3,368,473
| -24% | -$172M | 0.67% | 38 |
|
|
2023
Q4 | $705M | Sell |
13,763,893
-3,550,695
| -21% | -$186M | 0.93% | 11 |
|
|
2023
Q3 | $1,000M | Sell |
17,314,588
-89,166
| -0.5% | -$5.46M | 1.38% | 5 |
|
|
2023
Q2 | $1.11B | Sell |
17,403,754
-676,814
| -4% | -$45.4M | 1.49% | 3 |
|
|
2023
Q1 | $1.25B | Buy |
18,080,568
+4,286,479
| +31% | +$302M | 1.72% | 2 |
|
|
2022
Q4 | $992M | Buy |
13,794,089
+3,627,705
| +36% | +$274M | 1.34% | 5 |
|
|
2022
Q3 | $725M | Buy |
10,166,384
+5,161,226
| +103% | +$374M | 1.06% | 16 |
|
|
2022
Q2 | $385M | Buy |
5,005,158
+69,722
| +1% | +$5.31M | 0.54% | 60 |
|
|
2022
Q1 | $361M | Sell |
4,935,436
-11,389
| -0.2% | -$765K | 0.44% | 75 |
|
|
2021
Q4 | $308M | Buy |
4,946,825
+786,945
| +19% | +$46.2M | 0.37% | 87 |
|
|
2021
Q3 | $246M | Buy |
+4,159,880
| New | +$274M | 0.31% | 109 |
|
|
2019
Q2 | – | Sell |
-29,100
| Closed | -$1.39M | – | 665 |
|
|
2019
Q1 | $1.39M | Hold |
29,100
| – | – | ﹤0.01% | 595 |
|
|
2018
Q4 | $1.51M | Hold |
29,100
| – | – | ﹤0.01% | 595 |
|
|
2018
Q3 | $1.81M | Buy |
+29,100
| New | +$1.73M | ﹤0.01% | 627 |
|
|
2017
Q1 | – | Sell |
-82,000
| Closed | -$4.79M | – | 768 |
|
|
2016
Q4 | $4.79M | Hold |
82,000
| – | – | 0.01% | 506 |
|
|
2016
Q3 | $4.42M | Hold |
82,000
| – | – | 0.01% | 512 |
|
|
2016
Q2 | $6.03M | Hold |
82,000
| – | – | 0.01% | 458 |
|
|
2016
Q1 | $5.24M | Buy |
+82,000
| New | +$5.17M | 0.01% | 460 |
|
|
2014
Q4 | – | Sell |
-246,900
| Closed | -$12.6M | – | 723 |
|
|
2014
Q3 | $12.6M | Buy |
246,900
+24,200
| +11% | +$1.21M | 0.02% | 356 |
|
|
2014
Q2 | $10.8M | Buy |
222,700
+91,100
| +69% | +$4.49M | 0.02% | 379 |
|
|
2014
Q1 | $6.84M | Buy |
+131,600
| New | +$7M | 0.01% | 466 |
|
Other funds holding BMY
VCM
VPM
Boston Partners's BMY Position: Q1 2026 in Review
Boston Partners reduced its Bristol-Myers Squibb (BMY) stake by 11% in Q1 2026, selling an estimated $343K and leaving 48,532 shares worth $3.14M. The position accounts for ﹤0.01% of the portfolio, ranked #529.
Boston Partners first reported a position in BMY in Q1 2014 and has held it in 29 quarters since. The position peaked at $1.25B in Q1 2023. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Boston Partners held 48,532 shares of Bristol-Myers Squibb worth $3.14M as of Q1 2026.
- Boston Partners sold 5,890 Bristol-Myers Squibb shares in Q1 2026, an estimated $343K.
- Bristol-Myers Squibb made up ﹤0.01% of Boston Partners's portfolio in Q1 2026, its #529 holding.
- Boston Partners first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 29 quarters since.
- Boston Partners's Bristol-Myers Squibb position peaked at $1.25B in Q1 2023.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Boston Partners's 13F filing for Q1 2026, filed 11 May 2026.